KR20210057704A - Epac 억제제로서의 티에노[2,3-b]피리딘 유도체 및 이들의 약학적 용도 - Google Patents

Epac 억제제로서의 티에노[2,3-b]피리딘 유도체 및 이들의 약학적 용도 Download PDF

Info

Publication number
KR20210057704A
KR20210057704A KR1020207035139A KR20207035139A KR20210057704A KR 20210057704 A KR20210057704 A KR 20210057704A KR 1020207035139 A KR1020207035139 A KR 1020207035139A KR 20207035139 A KR20207035139 A KR 20207035139A KR 20210057704 A KR20210057704 A KR 20210057704A
Authority
KR
South Korea
Prior art keywords
group
alkyl
cycloalkyl
aryl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020207035139A
Other languages
English (en)
Korean (ko)
Inventor
쟝-폴 블롱듀
안토니오 콜루챠
마히옹 라우데뜨
프랭크 르저알크
Original Assignee
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
유니베르시떼 파리-싸끌레
사피엔자 유니버시타 디 로마
위니베르씨떼 뽈 싸바띠에 뚤루즈 3
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔), 유니베르시떼 파리-싸끌레, 사피엔자 유니버시타 디 로마, 위니베르씨떼 뽈 싸바띠에 뚤루즈 3 filed Critical 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
Publication of KR20210057704A publication Critical patent/KR20210057704A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020207035139A 2018-06-06 2019-06-06 Epac 억제제로서의 티에노[2,3-b]피리딘 유도체 및 이들의 약학적 용도 Pending KR20210057704A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305685 2018-06-06
EP18305685.2 2018-06-06
PCT/EP2019/064886 WO2019234197A1 (en) 2018-06-06 2019-06-06 Thieno[2,3-b]pyridine derivatives as epac inhibitors and their pharmaceutical uses

Publications (1)

Publication Number Publication Date
KR20210057704A true KR20210057704A (ko) 2021-05-21

Family

ID=62715982

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207035139A Pending KR20210057704A (ko) 2018-06-06 2019-06-06 Epac 억제제로서의 티에노[2,3-b]피리딘 유도체 및 이들의 약학적 용도

Country Status (6)

Country Link
US (1) US20210230179A1 (https=)
EP (1) EP3801511A1 (https=)
JP (1) JP7445609B2 (https=)
KR (1) KR20210057704A (https=)
CN (1) CN112638382B (https=)
WO (1) WO2019234197A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4072547A1 (en) * 2019-12-13 2022-10-19 Institut National De La Sante Et De La Recherche Medicale - Inserm Epac1 inhibitors for the treatment of idiopathic pulmonary fibrosis
WO2021250231A1 (en) * 2020-06-12 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Thienopyridine derivatives for use in the treatment of coronavirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60325051D1 (de) * 2002-06-06 2009-01-15 Boehringer Ingelheim Pharma SUBSTITUIERTE 3-AMINO-THIENO(2,3-b)PYRIDINE-2-AMIDE UND HERSTELLUNGSVERFAHREN SOWIE DEREN VERWENDUNG
AU2007275221A1 (en) * 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
US20110077250A1 (en) * 2009-06-26 2011-03-31 Ryder Sean Compounds for modulating rna binding proteins and uses therefor
US9751838B2 (en) 2012-10-02 2017-09-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tetrahydroquinoline derivatives and their use as Epac inhibitors
EP2928470A4 (en) * 2012-12-07 2015-12-16 Siga Technologies Inc THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity

Also Published As

Publication number Publication date
EP3801511A1 (en) 2021-04-14
JP2021527071A (ja) 2021-10-11
US20210230179A1 (en) 2021-07-29
CN112638382B (zh) 2024-10-18
CN112638382A (zh) 2021-04-09
JP7445609B2 (ja) 2024-03-07
WO2019234197A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
CN105189478B (zh) 脱氧尿苷三磷酸酶抑制剂
DK2688403T3 (en) OPIOID RECEPTOR LIGANDS AND METHODS FOR USING AND MANUFACTURING SAME
JP6513095B2 (ja) ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤
ES2787599T3 (es) Inhibidores de leucemia inv(16)
US8481553B2 (en) Antimetastatic compounds
RU2506261C2 (ru) Производные хиназолина
JP5747142B2 (ja) Ｄｙｒｋを阻害する化合物を含有する医薬組成物
ES3002432T3 (en) Rho kinase inhibitor ba-1049 (r) and active metabolites thereof
BR112017016392B1 (pt) Agente terapêutico para câncer do ducto biliar
EA015252B1 (ru) Способ модуляции стресс-активированной протеинкиназной системы
BRPI0805826B1 (pt) compostos espiro-substituídos, composição farmacêutica e uso
US20170333385A1 (en) Methods of Treating Hyperalgesia
WO2017006283A1 (en) Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
ES2958528T3 (es) Macrociclos sustituidos útiles como inhibidores de quinasas
JP2017516860A (ja) Ａｒｆ６阻害剤並びにそれらの合成方法及び使用
EP3661935B1 (en) Substituted pyrazolopyrimidines useful as kinases inhibitors
KR20210038906A (ko) 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
KR20210057704A (ko) Epac 억제제로서의 티에노[2,3-b]피리딘 유도체 및 이들의 약학적 용도
WO2012064396A9 (en) Novel ezrin inhibitors and methods of making and using
KR20220047807A (ko) 근육 소모 및 다른 상태의 치료 및 예방에 적합한 화합물
CN103044460A (zh) 3,5,7-三苯基-5H-噻唑并[3,2-a]嘧啶类衍生物及应用
KR20080072000A (ko) 신규 인돌리진 유도체, 그의 제조 방법 및 그것을 포함하는치료 조성물
WO2026041859A1 (en) Pak1 and/or pak2 activators and their use in the prevention and/or treatment of diseases or conditions
NZ615993B2 (en) Opioid receptor ligands and methods of using and making same
NZ713143B2 (en) Opioid receptor ligands and methods of using and making same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701